Pradaxa and its Risks

pradaxa and its riskA prescription anti-clotting drug known as Pradaxa by Behringer Ingelheim had first been approved in the European Union for sales and marketing on March of 2008. In the United States, Pradaxa was first approved for sale in October 2010. More than 1,000,000 prescriptions of Pradaxa have been prescribed for over 300,000 patients in U.S. since then. Recently, the Food and Drug Administration to evaluate the bleeding risks related with Pradaxa due to the uncommonly high reports of adverse effects. There are more than 200 fatal bleeding events reported worldwide between March 2008 and October 31, 2011. Patients who have subsequently suffered adverse events caused by prescribed Pradaxa may be entitled to compensation. Make contact with Pradaxa attorney for further information about your qualification to recover compensation.

Lots of patients are prescribed anticoagulants in order to avoid blood clotting or stroke in patients undergoing non valvular atrial fibrillation, knee replacement surgery, and hip replacement surgery. Hemorrhage side effects is not exceptional to Pradaxa, further blood-thinning drugs is report serious too as well as fatal bleeding as potential side effects. Though, Pradaxa related bleeding, be more risky than bleeding that caused by traditional, older blood thinners as there’s no remedy for direct thrombin inhibiters bleeding like Pradaxa.

The irresistible reports of fatal and serious bleeding have made the FDA to start further investigation about the drug Pradaxa. The failure rate might indicative of the unsafe drug formula.

If you know someone or may be yourself has experienced fatal bleeding which is associated with Pradaxa, it’s strongly recommended to seek advice from a defective drug attorney. Behringer Ingelheim as an International drug companies are agreeable to provide millions of dollars to protecting their product. Camberg Law Firm as a reputable firm has the experienced attorney to make sure your rightful compensation will not compromised.

Leave a Reply